Dexcom's Bold Move: CGMs for the Masses, With a Price Tag to Match

August 26, 2024

Imagine a world where tracking your blood sugar is as easy as picking up a pack of gum at the drugstore. Dexcom, the undisputed heavyweight champion of continuous glucose monitors (CGMs), has just thrown a wild punch with its new over-the-counter (OTC) device, the Stelo. No prescription. No gatekeepers. Just pure, unadulterated access to data that, until now, felt like it belonged to a secret society of the chronically ill. Welcome to the future, where even your glucose is just another app notification.

But before you grab your wallet and head to CVS, let's talk numbers. This little device isn’t exactly cheap. While Dexcom hasn’t released the price yet, if history is any indication, you’ll be shelling out a pretty penny. It's as if Dexcom is whispering, "You want convenience? Sure, but it's going to cost you." And it’s true—the convenience of having real-time glucose data without a prescription, without a doctor, without anyone between you and that sweet, sweet data is almost intoxicating. Almost. But then you remember the cost of freedom, and suddenly, your wallet feels a little lighter.

For those living with diabetes, this might be a game-changer. For everyone else, it’s another tech gadget to collect data they never knew they needed. And yet, here we are, teetering on the edge of a world where knowing your blood sugar is as routine as checking your email.

In the grand scheme of things, the Stelo represents more than just a new product. It’s Dexcom's big bet that the masses are ready to join the data-driven health revolution—provided they can afford the entry fee.

We don't offer subscriptions, but your support makes a difference: A QUICK REQUEST—If you found this story valuable, please consider donating to the Willamette Valley Observer. The work of local professionals like ours thrives on community support. Your contribution is fast, easy, and secure! https://www.willamettenews.com//_paylink/AZFXBvVX